文献速递泌尿男性生殖肿瘤

神经内分泌前列腺癌的临床特征

Clinical features of neuroendocrine prostate cancer.
PubMed 文献 · Eur J Cancer · 2019-09-13

该研究回顾了87例经活检确认神经内分泌前列腺癌(NEPC)的转移性前列腺癌患者的基线、治疗和结局数据,其中54.0%为原发NEPC,46.0%为治疗相关NEPC。中位年龄68.1岁,中位PSA为1.20 ng/ml,常见转移部位为骨(72.6%)、淋巴结(47.0%)和内脏(65.5%)。小细胞癌患者总生存期(8.9个月)显著短于混合型(26.1个月,P<0.001),原发NEPC总生存期也短于治疗相关NEPC(16.8个月 vs 53.5个月,P=0.043)。

要点

  • NEPC中位PSA较低(1.20 ng/ml),骨和内脏转移常见。
  • 小细胞癌总生存期(8.9个月)显著短于混合型(26.1个月,P<0.001)。
  • 原发NEPC总生存期(16.8个月)短于治疗相关NEPC(53.5个月,P=0.043)。

核心结论

  • NEPC患者中位年龄68.1岁,中位PSA为1.20 ng/ml,骨转移占72.6%,淋巴结转移占47.0%,内脏转移占65.5%。
  • 小细胞癌患者总生存期(8.9个月)显著短于混合型(26.1个月,P<0.001)。
  • 原发NEPC总生存期(16.8个月)短于治疗相关NEPC(53.5个月,P=0.043)。
  • 治疗相关NEPC前每月PSA上升≤0.7 ng/ml、乳酸脱氢酶升高、RB1和TP53缺失及肝转移为不良预后特征。

研究设计与样本

  • 回顾性队列研究,纳入87例经肿瘤活检确认NEPC组织学的转移性前列腺癌患者,其中47例(54.0%)为原发NEPC,40例(46.0%)为治疗相关NEPC。
  • 47例患者有基因组数据。

主要发现

  • 从腺癌至治疗相关NEPC诊断的中位时间为39.7个月(范围24.5-93.8),中位既往系统治疗线数为2线。
  • 57.5%的患者接受铂类化疗,中位无进展生存期为3.9个月。
  • 小细胞癌患者总生存期(8.9个月)显著短于混合型(26.1个月,P<0.001)。
  • 原发NEPC总生存期(16.8个月)短于治疗相关NEPC(53.5个月,P=0.043)。

关键数值与推荐

  • NEPC诊断时中位年龄68.1岁,中位PSA为1.20 ng/ml(小细胞癌0.14 ng/mL,混合癌1.55 ng/mL)。
  • 转移部位包括骨(72.6%)、淋巴结(47.0%)和内脏(65.5%)。
  • 57.5%的患者接受铂类化疗,中位无进展生存期为3.9个月。
  • 从腺癌至治疗相关NEPC诊断的中位时间为39.7个月(范围24.5-93.8),中位既往系统治疗线数为2线。
  • 治疗相关NEPC前每月PSA上升≤0.7 ng/ml、乳酸脱氢酶升高、RB1和TP53缺失及肝转移为不良预后特征。

临床怎么用

  • 对于具有低PSA、内脏转移或内分泌治疗快速进展等特征的前列腺癌患者,应考虑活检以明确NEPC组织学转化。
  • NEPC患者中铂类化疗常用,但无进展生存期较短,需探索更有效治疗策略。
  • 小细胞癌和原发NEPC预后更差,应加强监测和个体化治疗。

局限性

  • 回顾性研究设计,样本量有限(87例),可能存在选择偏倚。
  • 基因组数据仅47例患者可用,限制了分子特征分析。
  • 未报告对照人群或非NEPC患者的比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. Despite being important to recognise, the clinical features of NEPC are poorly defined and could help guide when to perform a biopsy to look for NEPC histologic transformation. METHODS: We reviewed baseline, treatment and outcome data of 87 patients with metastatic prostate cancer and tumour biopsy confirming NEPC histology. Forty-seven (54.0%) NEPC cases presented de novo, and 40 (46.0%) were therapy-related (t-NEPC). Thirty-six (41.4%) were classified as pure small-cell carcinoma, and 51 (58.6%) demonstrated mixed features with both small-cell carcinoma and adenocarcinoma present. Genomic data were available for 47 patients. RESULTS: The median age at time of NEPC was 68.1 years, median prostate-specific antigen (PSA) was 1.20 ng/ml (0.14 ng/mL small-cell carcinoma, 1.55 ng/mL mixed carcinoma) and sites of metastases included bone (72.6%), lymph node (47.0%), and viscera (65.5%). Median time from adenocarcinoma to t-NEPC diagnosis was 39.7 months (range, 24.5-93.8) with a median of two lines of prior systemic therapy. Platinum chemotherapy was used to treat 57.5% of patients, with a median progression-free survival of 3.9 months. Small-cell carcinoma was associated with worse overall survival (OS) than mixed histology (8.9 months from NEPC diagnosis versus 26.1 months, P < 0.001). Median OS of de novo NEPC was shorter than that of t-NEPC (16.8 months from prostate cancer diagnosis versus 53.5 months, P = 0.043). An average PSA rise per month of ≤0.7 ng/ml before t-NEPC; elevated lactate dehydrogenase levels, RB1 and TP53 loss and liver metastases were poor prognostic features. CONCLUSIONS: We describe the clinical features of a cohort of patients with NEPC. These characteristics may inform future diagnostic strategies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019. PMID: 31525487. doi:10.1016/j.ejca.2019.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。